Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines

Frank Bartel, Alan Taylor, Helge Taubert, Linda C. Harris

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Mdm2 is an oncogene that binds to and inactivates the tumor suppressor p53. However, the presence of oncogenic splice variants of mdm2 in human tumors that lack the p53 binding site has suggested a p53-independent transforming function for this protein. This report describes expression of 11 different mdm2 splice variants in pediatric rhabdomyosarcoma (RMS) cell lines and tumors at a frequency of 75% and 82%, respectively. Five of these isoforms have previously been described in other tumor histiotypes but six are novel and may be unique to RMS. There was no association between expression of splice variants and mdm2 gene amplification or p53 status. In addition, the frequency of splice variants was much higher than the incidence of mdm2 amplification or p53 mutations. These variants may be important to consider with respect to RMS tumor progression and therapeutic response.

Original languageEnglish (US)
Pages (from-to)451-457
Number of pages7
JournalOncology Research
Volume12
Issue number11-12
StatePublished - 2000
Externally publishedYes

Fingerprint

Rhabdomyosarcoma
Tumor Cell Line
Pediatrics
Neoplasms
Gene Amplification
Oncogenes
Protein Isoforms
Binding Sites
Mutation
Incidence
Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. / Bartel, Frank; Taylor, Alan; Taubert, Helge; Harris, Linda C.

In: Oncology Research, Vol. 12, No. 11-12, 2000, p. 451-457.

Research output: Contribution to journalArticle

Bartel, F, Taylor, A, Taubert, H & Harris, LC 2000, 'Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines', Oncology Research, vol. 12, no. 11-12, pp. 451-457.
Bartel, Frank ; Taylor, Alan ; Taubert, Helge ; Harris, Linda C. / Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. In: Oncology Research. 2000 ; Vol. 12, No. 11-12. pp. 451-457.
@article{69830a906d154976a63483b9e2a9d9aa,
title = "Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines",
abstract = "Mdm2 is an oncogene that binds to and inactivates the tumor suppressor p53. However, the presence of oncogenic splice variants of mdm2 in human tumors that lack the p53 binding site has suggested a p53-independent transforming function for this protein. This report describes expression of 11 different mdm2 splice variants in pediatric rhabdomyosarcoma (RMS) cell lines and tumors at a frequency of 75{\%} and 82{\%}, respectively. Five of these isoforms have previously been described in other tumor histiotypes but six are novel and may be unique to RMS. There was no association between expression of splice variants and mdm2 gene amplification or p53 status. In addition, the frequency of splice variants was much higher than the incidence of mdm2 amplification or p53 mutations. These variants may be important to consider with respect to RMS tumor progression and therapeutic response.",
author = "Frank Bartel and Alan Taylor and Helge Taubert and Harris, {Linda C.}",
year = "2000",
language = "English (US)",
volume = "12",
pages = "451--457",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "11-12",

}

TY - JOUR

T1 - Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines

AU - Bartel, Frank

AU - Taylor, Alan

AU - Taubert, Helge

AU - Harris, Linda C.

PY - 2000

Y1 - 2000

N2 - Mdm2 is an oncogene that binds to and inactivates the tumor suppressor p53. However, the presence of oncogenic splice variants of mdm2 in human tumors that lack the p53 binding site has suggested a p53-independent transforming function for this protein. This report describes expression of 11 different mdm2 splice variants in pediatric rhabdomyosarcoma (RMS) cell lines and tumors at a frequency of 75% and 82%, respectively. Five of these isoforms have previously been described in other tumor histiotypes but six are novel and may be unique to RMS. There was no association between expression of splice variants and mdm2 gene amplification or p53 status. In addition, the frequency of splice variants was much higher than the incidence of mdm2 amplification or p53 mutations. These variants may be important to consider with respect to RMS tumor progression and therapeutic response.

AB - Mdm2 is an oncogene that binds to and inactivates the tumor suppressor p53. However, the presence of oncogenic splice variants of mdm2 in human tumors that lack the p53 binding site has suggested a p53-independent transforming function for this protein. This report describes expression of 11 different mdm2 splice variants in pediatric rhabdomyosarcoma (RMS) cell lines and tumors at a frequency of 75% and 82%, respectively. Five of these isoforms have previously been described in other tumor histiotypes but six are novel and may be unique to RMS. There was no association between expression of splice variants and mdm2 gene amplification or p53 status. In addition, the frequency of splice variants was much higher than the incidence of mdm2 amplification or p53 mutations. These variants may be important to consider with respect to RMS tumor progression and therapeutic response.

UR - http://www.scopus.com/inward/record.url?scp=0034584527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034584527&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 451

EP - 457

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 11-12

ER -